S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:INMD

InMode (INMD) Stock Forecast, Price & News

$30.46
-0.49 (-1.58%)
(As of 09/29/2023 ET)
Compare
Today's Range
$30.08
$31.39
50-Day Range
$30.46
$45.03
52-Week Range
$28.51
$48.25
Volume
2.15 million shs
Average Volume
1.11 million shs
Market Capitalization
$2.53 billion
P/E Ratio
14.23
Dividend Yield
N/A
Price Target
$51.67

InMode MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
69.6% Upside
$51.67 Price Target
Short Interest
Bearish
9.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of InMode in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.51%
From $2.45 to $2.83 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

179th out of 972 stocks

Electromedical Equipment Industry

7th out of 20 stocks


INMD stock logo

About InMode (NASDAQ:INMD) Stock

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

INMD Price History

INMD Stock News Headlines

InMode Sees Unusually High Options Volume (NASDAQ:INMD)
The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
InMode: Bullish Support Failed To Materialize
InMode (INMD) Stock Moves -0.52%: What You Should Know
The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
InMode: Be Greedy When Others Are Fearful
Here's Why I'm Buying (More) InMode Stock in August
InMode (INMD) Q2 2023 Earnings Call Transcript
Are Medical Stocks Lagging InMode (INMD) This Year?
See More Headlines
Receive INMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

INMD Company Calendar

Last Earnings
7/27/2023
Today
10/01/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INMD
Fax
N/A
Employees
480
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$51.67
High Stock Price Forecast
$61.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+69.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$161.52 million
Pretax Margin
44.98%

Debt

Sales & Book Value

Annual Sales
$454.27 million
Cash Flow
$2.18 per share
Book Value
$6.68 per share

Miscellaneous

Free Float
77,236,000
Market Cap
$2.53 billion
Optionable
Not Optionable
Beta
2.11

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Yair Malca (Age 45)
    Chief Financial Officer
    Comp: $474k
  • Mr. Alon Yaari
    VP of Operations
  • Dr. Michael Kreindel (Age 55)
    CTO & Director
    Comp: $221k
  • Ms. Nava Tal-Launer
    Chief Information Officer
  • Mr. Shakil Lakhani (Age 40)
    Pres of North America
    Comp: $2.97M
  • Mr. Moshe Mizrahy (Age 70)
    Chairman & CEO
  • Dr. Spero Theodorou M.D. (Age 51)
    Chief Medical Officer













INMD Stock - Frequently Asked Questions

Should I buy or sell InMode stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InMode in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" INMD shares.
View INMD analyst ratings
or view top-rated stocks.

What is InMode's stock price forecast for 2023?

6 brokers have issued 1 year price targets for InMode's shares. Their INMD share price forecasts range from $40.00 to $61.00. On average, they expect the company's share price to reach $51.67 in the next twelve months. This suggests a possible upside of 69.6% from the stock's current price.
View analysts price targets for INMD
or view top-rated stocks among Wall Street analysts.

How have INMD shares performed in 2023?

InMode's stock was trading at $35.70 at the beginning of 2023. Since then, INMD shares have decreased by 14.7% and is now trading at $30.46.
View the best growth stocks for 2023 here
.

When is InMode's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our INMD earnings forecast
.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) released its earnings results on Thursday, July, 27th. The healthcare company reported $0.65 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.65. The healthcare company had revenue of $136.08 million for the quarter, compared to the consensus estimate of $135.80 million. InMode had a net margin of 36.77% and a trailing twelve-month return on equity of 35.03%.

When did InMode's stock split?

InMode shares split on Thursday, September 30th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly issued shares were distributed to shareholders after the market closes on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has InMode issued on next quarter's earnings?

InMode updated its FY23 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $2.62-$2.66 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $530-$540 million, compared to the consensus revenue estimate of $534.01 million.

What is Moshe Mizrahy's approval rating as InMode's CEO?

1 employees have rated InMode Chief Executive Officer Moshe Mizrahy on Glassdoor.com. Moshe Mizrahy has an approval rating of 100% among the company's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL).

When did InMode IPO?

(INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

What is InMode's stock symbol?

InMode trades on the NASDAQ under the ticker symbol "INMD."

How do I buy shares of InMode?

Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InMode's stock price today?

One share of INMD stock can currently be purchased for approximately $30.46.

How much money does InMode make?

InMode (NASDAQ:INMD) has a market capitalization of $2.53 billion and generates $454.27 million in revenue each year. The healthcare company earns $161.52 million in net income (profit) each year or $2.14 on an earnings per share basis.

How many employees does InMode have?

The company employs 480 workers across the globe.

Does InMode have any subsidiaries?
The following companies are subsidiares of InMode: Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..
Read More
How can I contact InMode?

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The official website for the company is www.inmodemd.com. The healthcare company can be reached via phone at 972-4909-7470 or via email at ir@inmodemd.com.

This page (NASDAQ:INMD) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -